Compare FEIM & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | CADL |
|---|---|---|
| Founded | 1961 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 280.3M |
| IPO Year | 1994 | 2021 |
| Metric | FEIM | CADL |
|---|---|---|
| Price | $48.11 | $4.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $42.50 | $18.50 |
| AVG Volume (30 Days) | 149.6K | ★ 1.3M |
| Earning Date | 06-15-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | 58.62 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $69,811,000.00 | $125,000.00 |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $186.64 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $14.41 | $4.25 |
| 52 Week High | $61.47 | $9.08 |
| Indicator | FEIM | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 36.72 |
| Support Level | $45.65 | $4.57 |
| Resistance Level | $59.91 | $6.16 |
| Average True Range (ATR) | 4.94 | 0.23 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 20.41 | 5.06 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.